Request Sample Inquiry
Cancer Biomarkers Market

Cancer Biomarkers Market

Cancer Biomarkers Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

146

Base Year:

2022

Date

May - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1613

Segments Covered
  • By Biomarkers Type By Biomarkers Type Protein Biomarkers, Genetic Biomarkers, Others
  • By Cancer Type By Cancer Type Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma Kidney Cancer, Others
  • By Profiling Technologies By Profiling Technologies Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics
  • By Application By Application Research & Development, Prognostics, Risk Assessment, Others
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 14.08 Billion
Revenue 2030Revenue 2030: USD 50.47 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 17.30%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst

Research Methodology: Cancer Biomarkers Market by Biomarkers Type by Cancer Type by Profiling Technologies by Application by Region - Global Market Assessment, 2021 - 2028

Secondary Research

Primary Research:

The next stage involves the primary research conducted to gather further information and revalidate the data collected from the secondary research. Moreover, primary research is also conducted to identify key players in the market and to gather their market-specific financial information. A typical primary interview fulfills data requirements pertaining to first-hand information global market size, regional and segmental trends, competitive landscape expertise development and market understandings among others. 

Data Triangulation and Market Size Estimations

Top-down and bottom-up approaches are used to validate and estimate the market size of the Cancer Biomarkers market. After the determination of the overall market size, the market is divided into various segments and sub-segments. Moreover, these same approaches mentioned above were used to derive and estimate market numbers for mentioned segments/sub-segments in the market. The data was triangulated by employing various data models and statistical techniques to arrive at exact statics and market size for each segment/sub-segment of the market.  

FAQ
Frequently Asked Question
  • The global Cancer Biomarkers valued at USD 14.08 Billion in 2022 and is expected to reach USD 50.47 Billion in 2030 growing at a CAGR of 17.30%.

  • The prominent players in the market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Qiagen N.V. (Netherlands), Illumina Inc. (US), Bio-Rad Laboratories Inc. (US), Abbott Laboratories (US), Bio Mérieux SA (US), Becton-Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics Inc. (US), Sysmex Corporation (Japan), Hologic Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems Inc. (US), BioVision Inc. (US), Olink (Sweden), Asuragen Inc. (US), Meso Scale Diagnostics LLC (US), Invivoscribe Inc. (US), Seegene Technologies Inc. (South Korea).

  • The market is project to grow at a CAGR of 17.30% between 2023 and 2030.

  • The driving factors of the Cancer Biomarkers include

    • Rising technological advancements in the development of cancer biomarkers

  • North America was the leading regional segment of the Cancer Biomarkers in 2022.